JP2023552919A - Ｗｎｔ受容体ｒｙｋに対する抗体バリアント - Google Patents

Ｗｎｔ受容体ｒｙｋに対する抗体バリアント Download PDF

Info

Publication number
JP2023552919A
JP2023552919A JP2023552151A JP2023552151A JP2023552919A JP 2023552919 A JP2023552919 A JP 2023552919A JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552919 A JP2023552919 A JP 2023552919A
Authority
JP
Japan
Prior art keywords
antibody
seq
ryk
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552919A5 (https=
Inventor
デイビッド エヌ． ハウザー，
テイラー エル． カンパート，
ミャオ スン，
Original Assignee
ベルサピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベルサピューティクス インコーポレイテッド filed Critical ベルサピューティクス インコーポレイテッド
Publication of JP2023552919A publication Critical patent/JP2023552919A/ja
Publication of JP2023552919A5 publication Critical patent/JP2023552919A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023552151A 2020-11-11 2021-11-08 Ｗｎｔ受容体ｒｙｋに対する抗体バリアント Pending JP2023552919A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112616P 2020-11-11 2020-11-11
US63/112,616 2020-11-11
PCT/US2021/058491 WO2022103705A1 (en) 2020-11-11 2021-11-08 Antibody variants against wnt receptor ryk

Publications (2)

Publication Number Publication Date
JP2023552919A true JP2023552919A (ja) 2023-12-19
JP2023552919A5 JP2023552919A5 (https=) 2024-10-24

Family

ID=81601681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552151A Pending JP2023552919A (ja) 2020-11-11 2021-11-08 Ｗｎｔ受容体ｒｙｋに対する抗体バリアント

Country Status (9)

Country Link
US (1) US20230416375A1 (https=)
EP (1) EP4244259A4 (https=)
JP (1) JP2023552919A (https=)
KR (1) KR20230107628A (https=)
CN (1) CN117295767A (https=)
AU (1) AU2021380681A1 (https=)
CA (1) CA3201419A1 (https=)
TW (1) TW202233683A (https=)
WO (1) WO2022103705A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172733A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532620A (ja) * 2001-02-19 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫原性の低減された人工タンパク質
US20160053022A1 (en) * 2013-04-03 2016-02-25 Peter Maccallum Cancer Institute Antibodies against human ryk and uses therefor
JP2017536101A (ja) * 2014-10-17 2017-12-07 グレンマーク ファーマシューティカルズ， エセ．アー． Ｃｃｒ６と結合する抗体およびその使用
JP2018520657A (ja) * 2015-05-29 2018-08-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
JP2019520788A (ja) * 2016-03-28 2019-07-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗Ｒｙｋ抗体およびその使用方法
JP2020508334A (ja) * 2017-02-24 2020-03-19 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
JP2020515239A (ja) * 2017-04-07 2020-05-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｉｃｏｓアゴニスト抗体およびそれらの使用
JP2020519308A (ja) * 2017-05-11 2020-07-02 アージェンクス・ベー・フェー・ベー・アー ＧＡＲＰ−ＴＧＦ−β抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236307B2 (en) * 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
EP3533803B1 (en) * 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP3828205A1 (en) * 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532620A (ja) * 2001-02-19 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫原性の低減された人工タンパク質
US20160053022A1 (en) * 2013-04-03 2016-02-25 Peter Maccallum Cancer Institute Antibodies against human ryk and uses therefor
JP2017536101A (ja) * 2014-10-17 2017-12-07 グレンマーク ファーマシューティカルズ， エセ．アー． Ｃｃｒ６と結合する抗体およびその使用
JP2018520657A (ja) * 2015-05-29 2018-08-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
JP2019520788A (ja) * 2016-03-28 2019-07-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗Ｒｙｋ抗体およびその使用方法
JP2020508334A (ja) * 2017-02-24 2020-03-19 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
JP2020515239A (ja) * 2017-04-07 2020-05-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｉｃｏｓアゴニスト抗体およびそれらの使用
JP2020519308A (ja) * 2017-05-11 2020-07-02 アージェンクス・ベー・フェー・ベー・アー ＧＡＲＰ−ＴＧＦ−β抗体

Also Published As

Publication number Publication date
TW202233683A (zh) 2022-09-01
AU2021380681A1 (en) 2023-06-15
KR20230107628A (ko) 2023-07-17
US20230416375A1 (en) 2023-12-28
EP4244259A1 (en) 2023-09-20
CA3201419A1 (en) 2022-05-19
CN117295767A (zh) 2023-12-26
AU2021380681A9 (en) 2024-02-08
WO2022103705A1 (en) 2022-05-19
EP4244259A4 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
CN104540522B (zh) 用于诊断和治疗癌症以及自身免疫病的单克隆抗体
JP6352812B6 (ja) 抗ｃｘｃｒ３抗体
TW201738273A (zh) 人類化抗pacap 抗體及其用途
TW201702266A (zh) 抗ｐａｃａｐ抗體及其用途
BR112020025502A2 (pt) Anticorpos il-11ra
CN113544150A (zh) 眼部病症中wnt信号传导的调节
BR112020017451A2 (pt) Composição farmacêutica para tratamento ou prevenção de ossificação heterotópica
JP2023552919A (ja) Ｗｎｔ受容体ｒｙｋに対する抗体バリアント
US20260109763A1 (en) Anti-pilra antibodies, uses thereof, and related methods and reagents
US20220002438A1 (en) Musk inhibition
EP3145545B1 (en) Bak binding proteins
HK40115111A (zh) 抗pilra抗体、其用途以及相关方法和试剂
TW202515915A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑
HK1208168B (zh) 用於诊断和治疗癌症以及自身免疫病的单克隆抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204